Research Article

DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY

Volume: 8 Number: 1 March 4, 2025
EN TR

DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY

Abstract

Objective: Saliva maintains vital mouth functions and acts as a barrier to dental health. Xerostomia, which is characterised as a feeling of dry mouth, adversely affects the patient’s quality of life. Palliative therapies, such as sialagogues, form the based on treatment of xerostomia. The FDAapproved sialagogue pilocarpine is currently recommended as the firstline medication for patients. Owing to its wide range of action, oral pilocarpine users may experience several negative side effects. The purpose of this study was to increase the duration of action and prevent systemic side effects of pilocarpine hydrochloride by designing and evaluating prolonged-release formulations of the drug using either xanthan gum, hydroxyethyl cellulose, or a combination of these two natural polymers buccal bioadhesive films. Material and Methods: The films were analysed for their physicochemical, mechanical, bioadhesive, swelling, in vitro release, and in vitro cytotoxicity. Results: Physicochemical and mechanical feature examinations revealed that the Xanthan-HEC combinations showed better results compared to the single polymer-used formulations. The in vitro dissolving profiles of all the optimal formulations showed a sustained release pattern with a steady-state plateau after an initial fast release. Using various release kinetic models to assess drug release kinetics revealed that the Higuchi and Korsmeyer-Peppas correlations are primarily followed by drug release from buccal films. Conclusion: The findings show that the mucoadhesive buccal formulation is a viable method for pilocarpine localised distribution that is both safe and effective in treating xerostomia. Further in vivo studies are planned to assess the pharmacokinetic and histopathological effects of the formulation.

Keywords

References

  1. Salum FG, Medella-Junior FAC, Figueiredo MAZ, Cherubini K. Salivary hypofunction: An update on therapeutic strategies. Gerodontology 2018;35(4):305-16. google scholar
  2. Nakagawa Y. Management of dry mouth in Sjögren’s syndrome. Japanese Dental Science Review 2011;47(2):115-23. google scholar
  3. Malallah OS, Garcia CMA, Proctor GB, Forbes B, Royall PG. Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth). Int J Pharm 2018;541(1-2):157-66. google scholar
  4. Shipp L, Liu F, Kerai-Varsani L, Okwuosa TC. Buccal films: A review of therapeutic opportunities, formulations & relevant evaluation approaches. J Controlled Release 2022;352:1071-92. google scholar
  5. Yildiz Pekoz A, Sedef Erdal M, Okyar A, Ocak M, Tekeli F, Kaptan E, et al. Preparation and in-vivo evaluation of dimenhydrinate buccal mucoadhesive films with enhanced bioavailability. Drug Dev Ind Pharm 2016;42(6):916-25. google scholar
  6. Dinte E, Muntean DM, Andrei V, Boşca BA, Dudescu CM, Barbu-Tudoran L, et al. In Vitro and In Vivo Characterisation of a Mucoadhesive Buccal Film Loaded with Doxycycline Hyclate for Topical Application in Periodontitis. Pharmaceutics 2023;15(2):580. google scholar
  7. Rençber S, Karavana SY, Yilmaz FF, Eraç B, Nenni M, Gurer-Orhan H, et al. Formulation and evaluation of fluconazole loaded oral strips for local treatment of oral candidiasis. J Drug Delivery Sci Tech 2019;49:615-21. google scholar
  8. Nafee NA, Ismail FA, Boraie NA, Mortada LM. Mucoadhesive buccal patches of miconazole nitrate: in vitro/in vivo performance and effect of ageing. Int J Pharmaceutics 2003;264(1):1-14. google scholar

Details

Primary Language

English

Subjects

Pharmaceutical Delivery Technologies

Journal Section

Research Article

Publication Date

March 4, 2025

Submission Date

July 17, 2024

Acceptance Date

October 28, 2024

Published in Issue

Year 2025 Volume: 8 Number: 1

APA
Akbal Dağıstan, Ö., Başarır, N. S., Karavana, S. Y., & Yıldız Peköz, A. (2025). DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY. Journal of Advanced Research in Health Sciences, 8(1), 34-41. https://doi.org/10.26650/JARHS2025-1517952
AMA
1.Akbal Dağıstan Ö, Başarır NS, Karavana SY, Yıldız Peköz A. DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY. Journal of Advanced Research in Health Sciences. 2025;8(1):34-41. doi:10.26650/JARHS2025-1517952
Chicago
Akbal Dağıstan, Özlem, Nur Sena Başarır, Sinem Yaprak Karavana, and Ayca Yıldız Peköz. 2025. “DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY”. Journal of Advanced Research in Health Sciences 8 (1): 34-41. https://doi.org/10.26650/JARHS2025-1517952.
EndNote
Akbal Dağıstan Ö, Başarır NS, Karavana SY, Yıldız Peköz A (March 1, 2025) DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY. Journal of Advanced Research in Health Sciences 8 1 34–41.
IEEE
[1]Ö. Akbal Dağıstan, N. S. Başarır, S. Y. Karavana, and A. Yıldız Peköz, “DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY”, Journal of Advanced Research in Health Sciences, vol. 8, no. 1, pp. 34–41, Mar. 2025, doi: 10.26650/JARHS2025-1517952.
ISNAD
Akbal Dağıstan, Özlem - Başarır, Nur Sena - Karavana, Sinem Yaprak - Yıldız Peköz, Ayca. “DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY”. Journal of Advanced Research in Health Sciences 8/1 (March 1, 2025): 34-41. https://doi.org/10.26650/JARHS2025-1517952.
JAMA
1.Akbal Dağıstan Ö, Başarır NS, Karavana SY, Yıldız Peköz A. DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY. Journal of Advanced Research in Health Sciences. 2025;8:34–41.
MLA
Akbal Dağıstan, Özlem, et al. “DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY”. Journal of Advanced Research in Health Sciences, vol. 8, no. 1, Mar. 2025, pp. 34-41, doi:10.26650/JARHS2025-1517952.
Vancouver
1.Özlem Akbal Dağıstan, Nur Sena Başarır, Sinem Yaprak Karavana, Ayca Yıldız Peköz. DEVELOPMENT AND EVALUATION OF BIOADHESIVE MUCOSAL DOSAGE FORMS OF PILOCARPINE HCL FOR XEROSTOMIA THERAPY. Journal of Advanced Research in Health Sciences. 2025 Mar. 1;8(1):34-41. doi:10.26650/JARHS2025-1517952